Alcon has acquired Israeli glaucoma treatment company Belkin Vision for approximately $335 million. Belkin Vision is the developer of the Eagle, an automated, contactless Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser for selective laser trabeculoplasty (SLT). The laser, which eliminates the need for a gonioscopy lens, received 510(k) clearance from the FDA last year. The acquisition was reported by Israeli ophthalmology investment company BioLight Industries, which reportedly received an immediate payment of NIS 9 million and was expected to receive additional milestone payments of up to $10.5 million for its 4% stake in the company.